ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1915

Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence

Brandon Jackson1, Roberto Caricchio2, Saira Sheikh3, Meenakshi Jolly4, Jennifer Meriwether5, Taylor Irons6, Taylor Adjei7, Caroline Donovan8, Carla Menezes7, Courtney Canton9, Aimee Williams10, Maya Merrell9 and Stacie Bell11, 1Lupus Therapeutics, Miami, FL, 2University of Massachusetts Chan Medical School, Worcester, MA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4Rush University, Chicago, IL, 5Lupus Therapeutics, Westminster, CO, 6Lupus Therapeutics, Houston, TX, 7Lupus Therapeutics, New York, NY, 8Lupus Therapeutics, Charlottesville, VA, 9Lupus Therapeutics, Charleston, SC, 10Lupus Therapeutics, Raleigh, NC, 11Lupus Therapeutics, Lakewood, CO

Meeting: ACR Convergence 2025

Keywords: Education, Minority Health, Surveys, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1914–1935) Health Services Research Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Lupus disproportionately impacts racial and ethnic minorities, yet these groups remain underrepresented in clinical trials. Lupus Therapeutics, overseeing the Lupus Clinical Investigators Network (LuCIN), conducts an annual survey to identify key operational challenges in trial recruitment. In recent years, social media and artificial intelligence (AI) have emerged as potential tools to enhance outreach and streamline operations. However, real-world adoption and effectiveness, especially to engage underrepresented populations, remains uncertain.

Methods: The 2025 LuCIN Annual Survey collected responses from 124 clinical staff across 60 North American sites (Dec 17, 2024, to Feb13, 2025). The survey addressed site use and perceptions of social media and AI tools, recruitment challenges, and preferred strategies to improve inclusion of underrepresented populations.

Results: Of the LuCIN members surveyed, 56% reported having bandwidth to use social media for recruitment, 61% did not find it effective, and 98% require IRB approval to use social media for recruitment. Nearly half (48%) have not used social media to reach the target audience for recruitment in clinical trials, whereas 28% have used social media video content, 27% professional content, and 25% paid advertisements (Table 1). AI adoption was more limited; 34% reported current use in work setting, while others noted policies in development or under review or not at all. Key perceived benefits of AI included translation support (60%), automated chart review (59%), assistance with source documentation (58%) and note-taking (53%). Respondents cited barriers such as institutional restrictions or ethics approvals, lack of trained personnel, and low patient yield (Table 2). 73% cited EDC query resolution challenges and 48% reported burdens associated with manual data transfer from EMRs, highlighting an area for AI to enable efficiencies. Many industry partners include third-party referrals for recruitment which only 16% found effective, supporting the use of alternative strategies. Online educational materials were endorsed by 81% of respondents as the most useful format for engaging patients. 46% prefer a patient navigation program for patients to connect with others in clinical trials. Despite these challenges, sites proposed strategies to advance the recruitment of historically underrepresented individuals relevant to social media including influencer or trusted community leader partnerships, digital campaigns through patient support groups, and educational global marketing campaigns Table 2.

Conclusion: Despite growing awareness of the potential of social media and AI in modernizing lupus trial recruitment, significant barriers limit their application. Widespread adoption is hindered by regulatory barriers, limited institutional support or bandwidth, and concerns about effectiveness and yield. To realize the promise of these tools, especially for engaging underrepresented populations, centralized resources, standardized training, and culturally tailored strategies must be prioritized. These findings support a targeted modernization roadmap for lupus clinical research.

Supporting image 1Table 1: Quantitative Feedback on Use of Social Media and Artificial Intelligence

Supporting image 2Table 2: Qualitative Feedback on Use of Social Media and Artificial Intelligence


Disclosures: B. Jackson: None; R. Caricchio: Abbvie, 1, Cabaletta, 5, GlaxoSmithKlein(GSK), 1, Kyverna, 5, Novartis, 1; S. Sheikh: AstraZeneca, 1, Aurinia Pharmaceuticals, 5, Biogen, 1, Cabaletta Bio, 5, GlaxoSmithKlein(GSK), 1; M. Jolly: AstraZeneca, 9, 10, chugai, 9, 10, 12, Chugai Pharmaceutical, e clin cloud technology, 9, 10, LRA, 1, Q32-Bio, 9, 10; J. Meriwether: None; T. Irons: None; T. Adjei: None; C. Donovan: None; C. Menezes: None; C. Canton: None; A. Williams: None; M. Merrell: None; S. Bell: None.

To cite this abstract in AMA style:

Jackson B, Caricchio R, Sheikh S, Jolly M, Meriwether J, Irons T, Adjei T, Donovan C, Menezes C, Canton C, Williams A, Merrell M, Bell S. Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/innovative-clinical-trial-recruitment-approaches-in-lupus-research-lucin-site-perspectives-on-use-of-social-media-and-artificial-intelligence/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/innovative-clinical-trial-recruitment-approaches-in-lupus-research-lucin-site-perspectives-on-use-of-social-media-and-artificial-intelligence/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology